Penserra Capital Management LLC Gemini Therapeutics, Inc. Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.22 - $1.73 $1,701 - $2,413	1,395 Added 13.99%	11,369 $19,000
Q1 2022 May 13, 2022	BUY	$1.29 - $3.08 $1,922 - $4,589	1,490 Added 17.56%	9,974 $13,000
Q4 2021 Feb 15, 2022	SELL	$2.39 - $4.0 $1,362 - $2,280	-570 Reduced 6.3%	8,484 $24,000
Q3 2021 Nov 15, 2021	BUY	$3.3 - $6.32 $8,180 - $15,667	2,479 Added 37.7%	9,054 $36,000
Q2 2021 Aug 12, 2021	SELL	$6.32 - $14.02 $42,110 - $93,415	-6,663 Reduced 50.33%	6,575 $42,000
Q1 2021 May 13, 2021	BUY	$11.32 - $18.0 $149,854 - $238,284	13,238 New	13,238 $179,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.